Localization for the Healthcare Sector in Europe: Compliance, Terminology, and Patient Communication

Legal Framework for Medical Devices and Pharmaceuticals in the EU

Localizing content for medical devices and pharmaceuticals in the EU is subject to strict regulatory requirements that vary depending on the product category and target country. Key regulations include Regulation (EU) 2017/745 on Medical Devices (MDR) and Regulation (EU) 536/2014 on clinical trials with medicinal products. For pharmaceuticals, Directive 2001/83/EC also applies. These regulations stipulate that instructions for use, labeling, and patient information must be provided in the official language(s) of the member state where the product is marketed. In practice, this means all translated texts must not only be linguistically correct but also legally compliant. Inadequate translation can lead to refusal of market authorization or liability risks.

A central point is the requirement for "notified body" certification for medical devices. The localized documentation must meet the same requirements as the original – including technical specifications, risk assessments, and clinical data. For pharmaceuticals, package leaflets and summary of product characteristics must be translated in accordance with the QRD templates of the European Medicines Agency (EMA). It is crucial to align terminology strictly with official European standards (e.g., EDQM, EU Pharmacopoeia). In practice, it is advisable to coordinate early with national authorities such as BfArM (Germany) or ANSM (France) to clarify language requirements. Additionally, translations should be validated by a designated language reviewer, especially for safety-related sections.

Recommendations: Conduct a legal gap analysis of language requirements for each product before starting translation. Assemble an interdisciplinary team of legal experts, medical professionals, and language specialists. Use translation management systems with versioning to track changes in the original documentation. Have all localized texts checked for accuracy by an independent, qualified person prior to publication – ideally with knowledge of the respective national legal framework. Note that subsequent corrections due to language errors are costly and time-consuming.

Data Protection Requirements under GDPR and Patients' Rights Directive

The processing of personal health data is subject to particularly stringent requirements under the General Data Protection Regulation (GDPR), supplemented by the Patients' Rights Directive (2011/24/EU). When localizing patient portals, e-health apps, or telemedicine platforms, all translated privacy policies and consent texts must comply with the requirements of Articles 13, 14, and 7 GDPR. The challenge lies in rendering complex legal formulations in the target language precisely and comprehensibly, without creating liability risks. In practice, simple translation is insufficient; rather, the localized text must meet national interpretations of the GDPR, which, for example, may be stricter in Germany due to supervisory authorities than in other EU countries.

For medical content, consent to data processing must also be worded so that the patient or user clearly understands its implications. This includes information about purposes, storage duration, and rights (access, deletion, data portability). The Patients' Rights Directive also requires that patients be informed in their language about treatment alternatives and quality standards. Therefore, localization should always adapt to country-specific legal terms – for example, the term "Einwilligung" in German versus "consent" in English, where legal nuances vary. A common mistake is the literal adoption of wording from the source text that has no legal equivalent in the target language.

Concrete recommendations: Work with a translator trained in data protection law who knows the national legislation. For consent texts, use bilingual glossaries reviewed by lawyers. Implement a multi-stage review process where the localized version is cross-checked by a local data protection advisor. Ensure that all changes to the original privacy policy are centrally managed and then updated accordingly. Document translation validation to demonstrate due diligence in case of disputes. Note that supervisory authorities scrutinize health data particularly closely – a flawed localization can lead to high fines. Therefore, seek legal advice on the specific requirements in each target country.

Terminology Management: Building and Maintaining Consistent Medical Glossaries

A consistent medical glossary is the backbone of any successful localization in the healthcare sector. It ensures that technical terms such as "myocardial infarction," "hypertension," or "adverse event" are used uniformly across all languages – regardless of whether the content is patient information, clinical studies, or package inserts. Without a central terminology database, inconsistencies easily arise: a term may be translated as "Herzinfarkt" in German, "infarctus du myocarde" in French, and "infarto miocardico" in Italian, while a later section suddenly uses "Herzmuskelinfarkt." This not only confuses patients but can also have regulatory consequences. In practice, it is advisable to build a multilingual glossary based on international standards such as SNOMED CT, ICD-10, or MedDRA.

Building begins by collecting all relevant terms from the source texts, sorted by category (e.g., anatomy, symptoms, medications, treatments). Each entry should include the German (or source language) term, a definition, the preferred translation in each target language, as well as synonyms and context examples. Crucially, links to regulatory references – for instance, whether a term is defined in the EU MDR or EMA guidelines – should be included. For maintenance, a regular update process is necessary since medical terminology evolves (e.g., new active substances). Use a cloud-based platform that is accessible to both translators and reviewers. When terms are translated for the first time in new content, the entry must be added to the glossary immediately – in practice, this is often omitted, leading to downstream errors.

Recommendations: Start with a baseline set of 200-500 terms that appear most frequently in your product portfolio. Commission medical professionals or specialist translators for initial maintenance and have the translations validated by native speakers with medical backgrounds. Integrate the glossary into your translation management system (TMS) so that it is automatically queried for each new translation. Train your translators to regard the glossary as binding – deviations should only be allowed after consultation with the terminology team. Conduct regular audits, cross-checking samples of localized text against the glossary. Only this ensures long-term consistency essential for patient safety and regulatory compliance. Remember: A well-maintained glossary also reduces translation time and minimizes the risk of costly correction cycles.

Source Text Optimization for Multilingual Translation and Localization

Optimizing source text is the first and crucial step for efficient and consistent localization of medical content. Source material such as patient information, instructions for medical devices, or clinical trial texts should already be structured in German so that they can later be translated into 24 languages. Avoid long nested sentences, metaphors, or culture-specific idioms that could be misunderstood in other languages. Instead, use clear, standardized formulations and separate instructions from background information.

A practical tool is creating a style guide with specifications for terminology, sentence length, and formatting. For example, define a maximum of 20 words per sentence and avoid passive constructions, as these lead to longer sentences in many languages. Also mark recurring text blocks in the source text (e.g., warnings or dosage information) as 'Translation Memories' (TMs). These are recognized as identical in the translation software and only need to be translated once. This increases consistency and reduces costs for updates.

For later localization into non-EU languages or highly variant languages like Arabic or Chinese, it is also recommended to use internationalization tags. Store placeholders for numbers, date formats, and currencies so that translators do not inadvertently copy incorrect formats. Have the source text reviewed by an internal expert for comprehensibility before translation. In practice, a test with five non-medical native speakers has proven effective: if they can correctly restate key statements in their own words, the text is suitable for translation.

Recommendation: Train your authors in 'Plain Language' principles and conduct regular audits of source texts. Invest in a Translation Management System (TMS) integration to centrally maintain TMs and terminology databases. Only optimized source text ensures that localized versions remain legally compliant and understandable for patients.

Regulatory and authority approval processes for localized content

Medical content in the EU is subject to strict regulatory requirements. Before localized texts such as package inserts, labeling, or patient portals go live, they often need to be reviewed by national authorities (e.g., BfArM in Germany, ANSM in France) or Notified Bodies. The approval process varies by country and product type. Therefore, plan a separate review cycle for each language. Document all changes traceably to be able to present verifiable versions in case of inquiries.

A proven approach is setting up a central review workflow in your TMS. Define a quality assurance phase for each market, where a local Regulatory Affairs manager checks the translated texts for compliance with national regulations. Special attention must be paid to warnings and safety information: these may neither be weakened nor supplemented in translation. Therefore, use Translation Memories containing already approved wording from authorities for such passages. Create a checklist for each country with specific requirements – e.g., for the positioning of pictograms or the length of instructions for use.

For clinical trials, patient information and consent forms must be available in the local language and additionally approved by the responsible ethics committee. Contact national contact points early to clarify deadlines and formal requirements. In practice, centralized translation management can shorten cycles: have all language versions reviewed in parallel, but ensure consistency between countries. Avoid considering approvals in one country as automatically valid for others – even with largely harmonized EU directives, there are national deviations.

Legal notice: This guide does not replace individual legal advice. For specific approval processes, consult a lawyer specialized in medical device law. Recommendation: Create a regulatory matrix for each target language country with contacts, review obligations, and typical turnaround times. This prevents delays in market entry.

Patient communication: comprehensibility and cultural sensitivity in 24 languages

Patient information must be not only legally accurate but also understandable for laypersons. Clarity heavily depends on language and culture: what is clear in German may seem too lengthy or technical in Polish or Italian. Therefore, use specific readability analyses for patient communication in 24 languages. Tools like the Flesch Reading Ease score in English or the Wiener Sachtextformel in German help adjust the level. The goal is typically a level equivalent to that of a 12- to 14-year-old. Adapt sentence length and word choice per country—more technical writing works in Scandinavia than in Southern Europe.

Cultural sensitivity is especially essential for health content. In some cultures, direct address ("You must...") is impolite, while in others a clear instruction is desired. Therefore, have native speakers—ideally with a medical background—not only review translations but also assess cultural nuances. For example, dosage instructions (splitting tablets, taking with meals) should be country-specific. Visual material must also be localized: symbols like a red cross or a specific skin color can evoke different associations.

For patient portals, the user guidance should be self-explanatory. Use internationally recognized icons (e.g., stethoscope for examination), but test them in each target culture. In addition to texts, offer audio or video versions, for instance for elderly or low-literacy patients. Involving patient representatives in the localization process can provide valuable feedback: Have three to five people from the target audience read through and test the localized texts for comprehension. In practice, such tests often show that seemingly simple terms like "side effect" have unknown or different nuances in some languages.

Recommendation: Develop a multilingual style guide chapter explicitly for patient communication with sample sentences and prohibited formulations. Conduct regular usability tests with representative users from each country. Only through this combination of translation, cultural adaptation, and review can the intended message reach patients.

Localization of Patient Portals and E-Health Applications

Patient portals and e-health applications must be not only legally compliant but also intuitively usable in all EU languages. A central aspect is compliance with the Medical Device Regulation (MDR) and the General Data Protection Regulation (GDPR). Ensure that all texts—from registration to displaying results—meet the regulatory requirements of each country. In practice, close collaboration with local legal advisors is recommended to account for country-specific peculiarities such as the French Loi Informatique et Libertés or German patient rights laws.

The user interface should be culturally adapted: colors, icons, and navigation elements can evoke different associations in different countries. For example, a calendar-based appointment booking system is preferred in Scandinavia, while a more personal approach with a chat function is expected in Southern Europe. Test the localized application with real users from the target group to identify usability issues early. An iterative process with feedback loops is critical for success.

Technically, you must ensure that internationalization (i18n) is cleanly implemented: text lengths vary greatly—a German sentence can be twice as long in Finnish. Therefore, plan flexible layouts that do not break even with longer texts. Additionally, medical terminology should be translated consistently; use a central glossary that is binding for all language versions. For e-health applications, pay particular attention to accessibility: EU Directive 2016/2102 requires digital accessibility for public sector bodies, which also applies to many health portals.

Recommendation: Define a style guide before localization that specifies language register, terminology, and cultural adaptations. Work with a translation management system (TMS) that supports medical glossaries and translation memories. Conduct an independent QA cycle for each language that includes both functional and content checks. Have the final content reviewed by a local medical law expert before releasing the application. This process minimizes legal risks and increases patient satisfaction.

Translation of Clinical Studies and Trial Plans in Compliance with ICH Guidelines

The translation of clinical studies and study protocols requires the highest precision, as errors can lead to regulatory delays or even rejection of approval. The International Council for Harmonisation (ICH) sets binding standards with guidelines E6 (GCP) and E3 (study reports). These require that translations be 'accurate, complete, and consistent'. In practice, this means: every term – from 'adverse event' to 'informed consent' – must be translated consistently and technically correctly into the target language. Avoid paraphrasing; adhere closely to ICH-recommended terminologies such as MedDRA for adverse events.

A common problem is the translation of clinical study protocols. These often contain legal and medical passages that must have the same legal effect in the target language. Therefore, exclusively use translators with medical and legal expertise. A two-step process has proven effective: first, a specialist translator translates the text, then a second expert (native speaker with medical background) checks the translation for technical accuracy and ICH compliance. Additionally, an editor should ensure register fidelity, especially for ethics committees and authorities that pay attention to country-specific formulations.

Care is also required for Case Report Forms (CRFs) and patient information. The informed consent form must be understandable for the patient but must not contain legal inaccuracies. In some EU countries, such as France or Poland, additional country-specific requirements for information must be observed. Therefore, have these texts reviewed by a local ethics committee or legal department before submission. A Translation Memory (TM) can help ensure consistent translations across multiple studies.

Recommendation: Create a project-specific glossary and style guide for each clinical study based on the ICH guidelines. Work with certified medical translators (e.g., according to EN 15038 or ISO 17100). Implement a four-eyes review process with technical and linguistic control. Document all translation steps transparently to demonstrate compliance to supervisory authorities such as the EMA. Invest in regular training of your translation team on changes to ICH guidelines and regulatory developments in the target countries.

Quality Assurance: Native Speaker Review and Medical Editing

Quality assurance in medical translations is not an optional step, but a regulatory necessity. In addition to technical accuracy, the localized version must also be linguistically and culturally suitable for the target audience. A proven method is the combination of native speaker review and medical editing. Native speaker review ensures that the text sounds idiomatic and fluent, while medical editing checks technical accuracy. In practice, both should be performed by different individuals to ensure independent control.

A concrete approach: After the raw translation (ideally by a specialist translator), an initial review is carried out by a medical expert who is a native speaker of the target language. This person checks terminology, dosage information, side effects, and other critical content. Subsequently, the text undergoes a second native speaker review covering purely linguistic aspects such as grammar, style, and cultural appropriateness. For patient materials, a comprehensibility test with laypersons from the target group is also recommended. This reveals whether medical terms are too complex or whether certain cultural concepts (e.g., 'informed consent' in Southern European countries) are misunderstood.

Technically, Translation Management Systems (TMS) support the QA process by tracking changes and comparing versions. Use quality metrics such as error rates per thousand words (e.g., <0.5 errors per 1000 words for critical texts). Document all review steps in a QA report that can be presented during audits. Note that the Medical Device Regulation (MDR) requires systematic review of translations – a one-time check is not enough; instead, changes to the source text must be re-localized and reviewed.

Recommendation: Define clear responsibilities and review paths for each step of quality assurance. Train your editors in both medical terminology and the specific requirements of EU regulations. Use automated checking tools (e.g., for terminology consistency) as a supplement, but not a replacement for human review. Conduct spot checks by external experts to validate quality. And: allow sufficient time for the QA phase – especially for multilingual projects with 24 languages, this is a critical success factor.

International SEO for Healthcare Websites: Legally Compliant Keyword Strategies

International SEO for health websites requires special care, as medical content is subject to strict legal regulations. Unlike other industries, you cannot simply translate keywords from the target language; you must account for local regulations. For example, Germany has the Therapeutic Advertising Act (HWG) and the Medicines Act (AMG), France has the Code de la Santé Publique, and Italy has the Codice del Consumo. Each country defines which terms are permissible claims. A keyword like "effective cancer therapy" may be classified as prohibited advertising in one country but allowed in another.

Practically, proceed as follows: start with comprehensive keyword research in each target language using tools like Google Keyword Planner or regional search engines. Pay attention not only to search volume but also to the legal admissibility of the terms. Engage a local legal expert for each country to review the keywords for compliance. For medical devices, you must consider EU Regulation 2017/745 (MDR) and national implementations. Avoid terms that imply unsubstantiated benefits.

Another important point is the localization of metadata such as title tags and meta descriptions. These must not only be search-engine optimized but also meet the same legal requirements as the visible text. Use clear, understandable language in all languages that makes no healing promises. Also, incorporate structured data (Schema.org) to correctly mark up medication information or doctor profiles, taking into account country-specific display requirements.

Finally, we recommend regular monitoring of the legal framework: what is allowed today may be prohibited tomorrow due to new rulings or guidelines. Therefore, schedule quarterly reviews of your keywords and content. Work with a network of native-speaking SEO specialists and legal experts who will inform you promptly of any changes.

Cost Calculation and Timeline for Multilingual Health Projects

Localizing medical content into 24 EU languages requires realistic cost and timeline planning. Experience shows that costs consist of several factors: translation volume (number of words), language combinations, required expert reviews, and legal approvals. For a patient portal with 50,000 words per language, the effort varies widely: for rarer languages like Maltese or Estonian, per-word prices are often higher than for Spanish or French. Additional costs include medical editing, which typically runs 30-50% above standard editing, and legal review by local law firms.

A proven approach is to create a detailed project structure plan. For each language, plan a separate timeline with the following phases: translation (including terminology work), medical editing by subject matter experts, legal review, possibly regulatory approval (e.g., for drug information), and quality assurance by native-speaking reviewers. For a medium-sized website (approx. 10,000 words per language), allow at least 4-6 weeks per language – for 24 languages, that’s at least 24-36 weeks total if you do not parallelize. By parallelizing work across multiple teams, the duration can be reduced to 8-12 weeks, but this requires tight coordination.

Concrete recommendation: for each language, budget a buffer of at least 20% for unforeseen queries or revisions from regulatory authorities. Use a detailed specification sheet for cost estimation that lists all services (translation, editing, review, potentially DTP) individually. Request quotes from your service provider with hourly rates for legal review – these typically range from €150 to €400 per hour, depending on the country and complexity. Plan monthly status meetings to track progress across all languages.

A common mistake is underestimating rework. After initial publication, expect feedback from authorities or patients that require adjustments. Therefore, include a maintenance contract for at least one year post-launch, covering updates and legal changes. Invest in a translation management system (TMS) with APIs to reduce recurring costs for identical text modules.

Checklist: Compliance Review Before Publishing Localized Content

Before publishing localized health content, conduct a multi-level compliance check. This checklist helps minimize legal risks—but does not replace legal advice. Structure the review into four areas: Medical Device Law/Pharmaceutical Law, Data Protection, Advertising Law, and Accessibility.

1. Medical Device Law/Pharmaceutical Law: Verify that all claimed indications and effects are supported by clinical data. Compare local approval statuses: A product approved in Germany may not be advertised in France with the same claims. Ensure correct CE marking and any national markings. For pharmaceuticals: Are all side effects and warnings translated according to the Summary of Product Characteristics? Do dosage instructions match the local market? Reference the original packaging if necessary.

2. Data Protection (GDPR and national supplements): Check that patient data in portals or apps is processed in accordance with the GDPR. Are all consent texts correctly translated and legally secure? Consider country-specific specifics such as in France (CNIL) or Germany (BfDI). Ensure that the imprint and privacy policy are available and complete in each language.

3. Advertising Law: Have all advertising claims, including on landing pages, reviewed by a local legal expert. Avoid superlatives such as 'best' or 'unique' without evidence. Misleading statements may lead to warnings. Ensure that testimonials are labeled as such and contain no unsubstantiated health promises.

4. Accessibility: Localized content must be accessible in all languages—e.g., plain language, alternative text for images, compliance with WCAG guidelines. This is partly required by law (e.g., EU Directive 2016/2102 for public bodies). Test the pages with screen readers in the respective language.

For each language, conduct a final review with a native-speaking medical editor who was not involved in the translation. Document all review steps in a review protocol and archive it for potential verification by regulatory authorities. Set a publication freeze until all points are checked.

Pitfalls and Common Mistakes in Localizing Pharma Websites

Localizing pharma websites into 24 EU languages carries specific risks beyond mere translation errors. A typical pitfall is inadequate adaptation to national approval statuses. An active ingredient may be approved for indication A in Germany but only for indication B in France. If texts are not differentiated by country, there is a risk of warnings for misleading advertising. Therefore, before localization, check for each target country the current Summary of Product Characteristics and package leaflets from the respective national authorities (e.g., BfArM, ANSM).

Another common mistake concerns the use of unauthorized claims. Even if a sentence is correct in the source language, a literal translation in the target market may violate therapeutic advertising law. Example: A general statement like 'supports natural defenses' may be considered a permitted health claim in one country but an unauthorized therapeutic claim in another. Therefore, work with a legal advisor for each country who knows the local advertising regulations (e.g., HWG in Germany, AMG in Austria). Have each claim legally reviewed in advance.

Cultural misunderstandings are also risky. Color coding, symbols, or image motifs can evoke different associations in different countries. A neutral image of a tablet in Scandinavia may be perceived as impersonal in Southern European countries. Medical devices should be adapted in illustrations to local practice—e.g., syringes with country-specific scales. Don't forget to translate legal disclaimers like 'prescription-only' or 'pharmacy-only' specific to each country and place them in the correct locations.

Finally, neglecting formatting requirements leads to errors. Many pharma websites must display certain warnings in a minimum font size or with specific spacing. During localization, these are often copied without accounting for text length. A long German warning may be shorter in English, breaking the layout—or vice versa. Use flexible templates and test the display in all languages on mobile devices. Before publication, conduct a full legal review of the localized content (see checklist in the previous chapter).

Outlook: AI-Powered Translation and Regulatory Developments in the EU

The use of Artificial Intelligence (AI) for translating medical content is increasing, but it presents particular challenges in regulated areas. Current neural machine translation systems such as GPT-based models can produce fluent texts, but they often lack understanding of specialized terminology and regulatory nuances. In practice, AI translations for general patient information (e.g., dietary guides) are acceptable after careful post-editing. However, for critical texts such as adverse event reports or dosage instructions, full human translation with medical expert review is still required.

Meanwhile, the EU is preparing new regulatory frameworks that also affect localization. The proposed Artificial Intelligence Act (AI Act) classifies medical translation systems as high-risk applications when used in patient communication. This means stricter requirements for training data, transparency, and human oversight in the future. Companies using AI for localization should establish quality assurance documentation processes early on. Fully automated translation without human control will not be permissible in regulated areas even in the medium term.

Another trend is the harmonization of terminology databases. The European Medicines Agency (EMA) and national authorities are working on standardized multilingual vocabularies (e.g., EDQM standards). Localization projects should leverage these sources to ensure consistency across all EU languages. For companies, this means regularly aligning their glossaries with regulatory requirements—a step often neglected in projects.

Recommendation: Build a tiered translation model. For real-time chatbots or FAQ sections, AI pre-translation with subsequent medical review may suffice. For legally binding texts (package inserts, clinical studies), continue to rely on specialized human translators. Monitor developments in the AI Act and adapt your compliance processes in a timely manner. Seek advice from a lawyer specialized in medical law on specific requirements—the legal landscape is dynamic and varies by product type and target country.

Partnering with Specialized Translation Service Providers in Healthcare

Selecting the right service provider for localizing health content requires careful scrutiny. Ensure that the provider has demonstrable expertise in the medical and pharmaceutical fields. Ask for references from the sector, particularly projects that had to comply with regulatory requirements such as the Medical Device Regulation (MDR) or ICH guidelines for clinical studies. A competent provider will assemble a team of native-speaker translators with a medical background, as well as subject matter experts and, if needed, regulatory affairs consultants.

Clarify in advance how the provider ensures terminological consistency. In practice, using a central glossary and translation memory system (TM) has proven effective. Demand insight into quality assurance processes: Are translations always reviewed by a second subject matter expert? Is there a comparison with the source text to avoid interpretation errors? For GDPR compliance, a data processing agreement (DPA) is essential, as patient data or sensitive study data may be processed.

Another point is communication culture. For complex projects with multiple languages, dedicated points of contact and regular status meetings are recommended. Define escalation paths for content questions not covered by the glossary. In practice, close collaboration between your expert team and the provider reduces error rates—for example, when changes to source terminology are communicated immediately to the translator. Also check tool compatibility: If your content management system requires specific export formats, the provider should support them, otherwise additional conversion effort arises.

Include binding delivery deadlines in the contract and agree on a process for change requests after translation has been completed. Note: Iterations may occur during regulatory approval. An experienced provider offers flexible review cycles for this purpose. Always obtain your own legal advice before commissioning, particularly on liability issues for incorrect translations of safety warnings or package inserts. The quality of collaboration significantly determines the compliance of your localized content.

Common Objections to Professional Localization and How to Address Them

In the healthcare sector, decision-makers often encounter reservations about comprehensive localization projects. A recurring objection is the high cost. Instead of arguing in general terms, you can compare costs and benefits: Incorrect translations can lead to claims for recourse, market withdrawals, or reputational damage. Use concrete examples from your industry—for instance, a case where an inaccurate dosage instruction led to a recall. In practice, quality investments pay off through avoided liability risks. Point out that professional localization does not have to be more expensive than subsequent corrections, which often cost many times more.

A second objection is: 'Machine translation is enough.' Here you can cite regulatory requirements: Machine translation alone does not meet MDR readability requirements or GDPR requirements for patient data. AI translations often produce nonsensical errors in technical terms, such as confusing 'intravenous' and 'intramuscular.' Explain that even the best AI only serves as a starting point and that native-language review by medical professionals is indispensable. For legally mandated texts such as instructions for use or study protocols, responsibility cannot be delegated to a machine.

Third objection: 'Our target audience also understands English.' This may apply to certain professional groups, but for patient information and lay communication, the native language is crucial. The EU Patients' Rights Directive requires information in the patient's language; otherwise, approvals may be refused. Argue that even doctors in non-English-speaking countries prefer localized versions to avoid misinterpretation.

A fourth objection concerns time: 'This delays our launch.' Here, realistic project plans with parallel work streams help. By involving the service provider early and using modular translation, many languages can be processed in parallel. Show that a terminology and TM system set up once saves time on subsequent projects. Important: For all objections, you should always refer to your specific situation and recommend, if in doubt, consulting legal advice to clarify the regulatory consequences of not localizing.

Practical Implementation: Step-by-Step Localization of a Drug Information

A concrete example can illustrate the process of professional localization in the healthcare sector. Take a German-language package leaflet for a fictitious medication that you want to have translated into French. Your goal is compliance with EU Directive 2001/83/EC and readability for patients. Step 1: Preparation – Extract the source text from your content management system and clean up formatting. Create a glossary of key technical terms (e.g., active ingredient name, dosage form, side effects). Step 2: Translation – Hand over the file along with the glossary and reference materials to a medical technology specialist translator whose native language is French. The translator works in a CAT tool to leverage translation memories. Step 3: Terminology check – After the initial translation, the terminologist compares the terms used with your specifications. Inconsistencies are flagged. Step 4: Expert review – A second experienced medical translator performs a review. They check for technical accuracy, register, and readability. Step 5: Compliance check – A lawyer with experience in French pharmaceutical law checks compliance with local regulations (e.g., warnings, side effect lists). Step 6: DTP and formatting – The translated package leaflet is fitted into the layout. Pay attention to line breaks and font sizes that remain readable for patients. Step 7: Quality assurance – A final native-language proofreading without time pressure ensures no typos or formatting errors remain. Step 8: Approval – Before approval by the responsible person (e.g., Qualified Person), have a final validation carried out. Document all steps for audit trails. In practice, it has proven useful to create a project plan with milestones for each target language. Allow about 2–3 weeks for a text of 2000 words. Note that regulatory reviews can take additional time. Legal advice on the requirements of the French ANSM (Agence Nationale de Sécurité du Médicament) is recommended, as national peculiarities can influence approval.